Hospital
Desert Springs Hospital
Desert Springs Hospital was paid $22.29M by Medicaid between Jan 2018 and Jul 2023, across 230 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoDESERT SPRINGS HOSPITAL
LAS VEGAS, NV 89119
LAS VEGAS, NV 89119
33aNPI1154317964assigned 09/27/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.29M
24GClaims1,048,017
24DCodes billed230
24AFirst – last monthJan 2018 – Jul 2023
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#11 of 36
Median peer was paid$7.64M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 111,371 | $1.82M | |
| 2019 | 260,093 | $5.38M | |
| 2020 | 201,149 | $4.22M | |
| 2021 | 215,313 | $4.69M | |
| 2022 | 193,102 | $4.58M | |
| 2023 | 66,989 | $1.60M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 42,161 | 34,552 | $4.62M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 24,638 | 21,543 | $2.26M |
| G0378 | Hospital observation service, per hour | 9.6% | 18,145 | 13,423 | $2.13M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.9% | 6,729 | 5,673 | $1.54M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.0% | 25,980 | 20,890 | $1.33M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.7% | 5,228 | 4,466 | $820K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 9,082 | 7,691 | $723K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.7% | 2,554 | 2,125 | $601K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.4% | 22,466 | 17,577 | $544K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 30,146 | 23,611 | $520K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.1% | 1,052 | 891 | $461K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 23,504 | 17,673 | $441K |
218 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 24,650 | $416K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 19,390 | $271K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.1% | 2,016 | $255K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 6,725 | $228K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,041 | $213K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,711 | $213K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,784 | $205K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,573 | $196K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 62,705 | $190K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 34,736 | $164K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,440 | $157K |
| 80053 | Comprehensive metabolic panel | <1% | 34,420 | $154K |
| 71045 | Radiologic examination, chest; single view | <1% | 24,239 | $148K |
| 0450 | Emergency room services | <1% | 3,717 | $144K |
| 84484 | <1% | 32,227 | $127K | |
| 72131 | <1% | 985 | $122K | |
| 96376 | <1% | 9,680 | $116K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 74,739 | $103K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 31,707 | $101K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,739 | $99K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 820 | $94K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,327 | $94K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 959 | $87K |
| 83880 | <1% | 7,877 | $83K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,196 | $82K |
| 84702 | <1% | 12,111 | $82K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,741 | $81K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,050 | $79K |
| 93971 | <1% | 1,717 | $74K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,150 | $68K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,033 | $66K |
| 70486 | <1% | 505 | $65K | |
| 93970 | <1% | 959 | $63K | |
| 76801 | <1% | 955 | $57K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,832 | $54K |
| 90715 | <1% | 1,305 | $53K | |
| 83690 | <1% | 18,118 | $51K | |
| 83605 | <1% | 11,564 | $46K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,053 | $46K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 16,517 | $40K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,199 | $37K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,428 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,149 | $34K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,149 | $34K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,011 | $34K |
| 70496 | <1% | 104 | $33K | |
| 73564 | <1% | 1,774 | $31K | |
| 70498 | <1% | 137 | $31K | |
| 87040 | <1% | 6,692 | $30K | |
| 10060 | <1% | 423 | $29K | |
| 81001 | <1% | 22,174 | $29K | |
| 81025 | <1% | 10,651 | $28K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,843 | $28K |
| 85730 | <1% | 14,444 | $28K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,563 | $26K |
| 83735 | <1% | 11,751 | $25K | |
| 73630 | <1% | 1,708 | $25K | |
| 73130 | <1% | 1,356 | $24K | |
| 85610 | <1% | 17,878 | $22K | |
| 73610 | <1% | 1,288 | $21K | |
| 85379 | <1% | 5,317 | $21K | |
| 97162 | <1% | 875 | $18K | |
| 93017 | <1% | 1,075 | $18K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 177 | $18K |
| 73030 | <1% | 1,300 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,700 | $17K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,789 | $17K |
| 94664 | <1% | 2,723 | $17K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,002 | $17K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,750 | $16K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,308 | $15K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,032 | $15K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 301 | $15K |
| 87186 | <1% | 4,271 | $15K | |
| 82550 | <1% | 5,655 | $14K | |
| 80061 | Lipid panel | <1% | 3,280 | $14K |
| 72100 | <1% | 998 | $14K | |
| 87641 | <1% | 1,677 | $13K | |
| 80076 | <1% | 4,018 | $13K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,747 | $13K |
| Z7502 | <1% | 350 | $13K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 109 | $12K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,344 | $12K |
| 96367 | <1% | 804 | $11K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,393 | $11K |
| 73110 | <1% | 516 | $11K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,570 | $11K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,968 | $11K |
| 82962 | <1% | 16,600 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,749 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,337 | $10K |
| 70491 | <1% | 63 | $10K | |
| 94644 | <1% | 440 | $9K | |
| 93880 | <1% | 153 | $9K | |
| J3490 | Unclassified drugs | <1% | 639 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,089 | $9K |
| 93458 | <1% | 14 | $9K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,097 | $9K |
| 80074 | <1% | 483 | $8K | |
| 97166 | <1% | 403 | $8K | |
| 81003 | <1% | 9,606 | $8K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,467 | $7K |
| 85027 | <1% | 4,128 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,285 | $6K |
| J2358 | Injection, olanzapine, long-acting, 1 mg | <1% | 349 | $6K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,931 | $6K |
| 71101 | <1% | 336 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 520 | $5K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 40 | $5K |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 162 | $5K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,230 | $5K |
| 84439 | <1% | 1,347 | $5K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 245 | $5K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,324 | $4K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,443 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,346 | $4K |
| 74022 | <1% | 171 | $4K | |
| 82803 | <1% | 729 | $4K | |
| 80069 | <1% | 2,055 | $4K | |
| 73502 | <1% | 248 | $4K | |
| 95816 | <1% | 34 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,767 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 66 | $3K |
| 86140 | <1% | 1,673 | $3K | |
| 84145 | <1% | 378 | $3K | |
| 82140 | <1% | 607 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,799 | $3K |
| 97116 | <1% | 490 | $3K | |
| 0270 | <1% | 505 | $3K | |
| 0250 | <1% | 206 | $3K | |
| 86900 | <1% | 2,234 | $3K | |
| 86901 | <1% | 2,234 | $3K | |
| 86850 | <1% | 1,433 | $2K | |
| 72040 | <1% | 145 | $2K | |
| 73590 | <1% | 161 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,349 | $2K |
| 84100 | <1% | 1,186 | $2K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 181 | $2K |
| 87077 | <1% | 473 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 380 | $2K |
| 71250 | <1% | 31 | $2K | |
| 87205 | <1% | 1,188 | $2K | |
| 87210 | <1% | 806 | $2K | |
| 85652 | <1% | 1,507 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,259 | $2K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 52 | $2K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,824 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,971 | $2K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 339 | $1K |
| 96368 | <1% | 164 | $1K | |
| 90686 | <1% | 192 | $1K | |
| 82010 | <1% | 457 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,613 | $1K |
| 29125 | <1% | 62 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 19 | $1K |
| 87070 | <1% | 605 | $1K | |
| 97165 | <1% | 29 | $1K | |
| 87275 | <1% | 345 | $1K | |
| 84132 | <1% | 1,042 | $1K | |
| 72128 | <1% | 13 | $1K | |
| 99070 | <1% | 135 | $1K | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 424 | $1K |
| G0008 | Administration of influenza virus vaccine | <1% | 194 | $999.30 |
| 74018 | <1% | 88 | $940.87 | |
| 87276 | <1% | 344 | $911.30 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 321 | $870.00 |
| 97161 | <1% | 37 | $861.53 | |
| 97163 | <1% | 31 | $778.17 | |
| C1781 | Mesh (implantable) | <1% | 28 | $756.00 |
| 73080 | <1% | 61 | $730.33 | |
| 76870 | <1% | 26 | $636.46 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 145 | $634.29 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 46 | $514.37 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 24 | $513.10 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 234 | $449.57 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,294 | $445.41 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 103 | $394.66 |
| 82150 | <1% | 134 | $393.82 | |
| 83615 | <1% | 157 | $386.61 | |
| 76775 | <1% | 16 | $378.87 | |
| 36600 | <1% | 78 | $371.79 | |
| 99152 | <1% | 97 | $275.01 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 68 | $268.38 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 271 | $266.22 |
| 82728 | <1% | 76 | $260.40 | |
| 87081 | <1% | 175 | $221.84 | |
| 82607 | <1% | 39 | $175.81 | |
| 82805 | <1% | 12 | $175.45 | |
| 73060 | <1% | 14 | $153.10 | |
| 87631 | <1% | 274 | $146.58 | |
| 73090 | <1% | 13 | $129.20 | |
| Z7610 | <1% | 14 | $127.90 | |
| A9270 | Non-covered item or service | <1% | 18,925 | $125.71 |
| 72170 | <1% | 14 | $107.82 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 13 | $102.00 |
| C1769 | Guide wire | <1% | 601 | $87.59 |
| 85347 | <1% | 33 | $78.58 | |
| 85018 | <1% | 131 | $75.03 | |
| 86780 | <1% | 13 | $73.14 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 58 | $68.76 |
| 85014 | <1% | 97 | $57.11 | |
| 87184 | <1% | 15 | $51.81 | |
| 99000 | <1% | 14 | $50.82 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 111 | $45.27 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 33 | $42.57 |
| 83540 | <1% | 19 | $35.01 | |
| 83550 | <1% | 16 | $33.46 | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 24 | $26.67 |
| 87430 | <1% | 32 | $11.53 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 39 | $2.50 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 118 | $0.01 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 132 | $0.01 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 36 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 83 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 709 | $0.00 |
| 0353U | 0% | 292 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 145 | $0.00 |
| C1729 | Catheter, drainage | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR, VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Doctors Hospital of Laredo | Laredo, TX | $52.31M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.